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Background: The objective of the study was to formulate and to investigate the combined influence of 3
independent variables in the optimization of Polymeric lipid hybrid nanoparticles (PLHNs) (Lipomer) containing
hydrophobic antifungal drug Itraconazole and to improve intestinal permeability.
Method: The Polymeric lipid hybrid nanoparticle formulation was prepared by the emulsification solvent evaporation
method and 3 factor 3 level Box Behnken statistical design was used to optimize and derive a second order polynomial
equation and construct contour plots to predict responses. Biodegradable Polycaprolactone, soya lecithin and Poly vinyl
alcohol were used to prepare PLHNs. The independent variables selected were lipid to polymer ratio (X1) Concentration
of surfactant (X2) Concentration of the drug (X3).
Result: The Box-Behnken design demonstrated the role of the derived equation and contour plots in predicting the
values of dependent variables for the preparation and optimization of Itraconazole PLHNs. Itraconazole PLHNs revealed
nano size (210 ± 1.8 nm) with an entrapment efficiency of 83 ± 0.6% and negative zeta potential of −11.7 mV and also
enhance the permeability of itraconazole as the permeability coefficient (Papp) and the absorption enhancement ratio
was higher.
Conclusion: The tunable particle size, surface charge, and favourable encapsulation efficiency with a sustained drug
release profile of PLHNs suggesting that it could be promising system envisioned to increase the bioavailability by
improving intestinal permeability through lymphatic uptake, M cell of payer’s patch or paracellular pathway which was
proven by confocal microscopy.
Keywords: Polymeric lipid hybrid nanoparticles, Box-behnken design, Entrapment efficiency, Drug loading, OptimizationBackground
The frequency of acquiring bacterial, viral, or fungal in-
fectious diseases increase each year due to the ease of
transmission from person to person. From many forms
of the infection, invasive fungal infections have become
more common in recent years, with a nearly 500%
growth in the incidence of blood stream infection with
Candida spp. since the 1980 [1]. The azole antifungal
agents represent a major drug class in the treatment of
wide variety of fungal infections. These drugs can be* Correspondence: balaramgajra.ph@charusat.ac.in
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unless otherwise stated.divided in two main groups: the imidazoles and the tria-
zoles [2].
Itraconazole (ITZ) is a potent triazole antifungal with
broad spectrum of activity against fungal species and
more efficacious for the treatment of both systemic and
superficial fungal infections [3]. ITZ is widely clinically
used for a variety of serious fungal infections in normal
and immunocompromised hosts, including Aspergillosis,
Cryptococcus, Candida, Blastomyces, disseminated Peni-
cillium mameffei infections and Histoplasma capsulatum
var. capsulatum and also it has less nephrotoxicity than
Amphotericin B [4].
One of the problem with ITZ is its highly hydrophobic
characteristics and extremely weak basicity with aqueous
solubility of approximately 1 ng/ml at neutral pH [2].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Variables and levels in Box-Behnken design
Level
Independent variables −1 0 +1
X1 Lipid to Polymer ratio 1:1 1:5 1:10
X2 Concentration of surfactant (% w/v) 0.5% 1% 1.5%
X3 Concentration of drug (% w/v) 0.06% 0.12% 0.18%
Dependent variables
Y1 Particle Size (nm)
Y2 % Entrapment Efficiency (nm)
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mulation of the ITZ are not allowed to be used in pa-
tients with impaired renal function and aged person. It
is not because of the toxicity of the drug itself, but the
adjuvant hydroxypropyl-β-cyclodextrin (HP-β-CD). Each
milliliter of Sporanox® solution and capsule contains
10 mg of ITZ solubilised by 400 mg of HP-β-CD as an
inclusion complex. Following a single intravenous dose
of 200 mg Sporanox® to the subjects with severe renal
impairment, clearance of HP-β-CD was 6-fold reduced
compared with subjects with normal renal function [3].
Hence, a development of oral formulation of ITZ with-
out HP-β-CD is very much important.
The classical polymer lipid hybrid nanoparticles (PLHN)
are composed of liposomes and polymeric nanoparticles
into a single delivery system. This type of nanoparticles
are typically comprised of two distinct functional compo-
nents: (i) a hydrophobic or hydrophilic polymeric core
where poorly water-soluble or highly water soluble drugs
are incorporated with high loading yields; (ii) a lipid layer
surrounding the core that acts as a highly biocompatible
shell and as a molecular fence to promote drug retention
inside the polymeric core [5].
There are several pathways used by molecules to cross
the epithelial cell barrier, which include transcellular
(transport through the cell, with crossing of the cell
membranes), paracellular (transport between adjacent
cells), and transcytosis through enterocytes. Transcellular
pathways through M cells is one of the mechanisms to
transport nanoparticles across the intestinal barrier. M cells
are associated with Peyer’s Patches (PP), an organized com-
ponent of the gut-associated lymphoid tissue (GALT) [6].
M cells have several properties that allow for adherence by
NPs, such as reduced proteases, lack of mucus secretion,
and a sparse glycocalyx [7]. A number of approaches have
been used to target nanoparticles to M cells. Various
nanoparticles like chitosan nanoparticle [8,9], solid lipid
nanoparticle [10], polymeric nanoparticle [11-13] and
nanoemulsion [14] are capable of enhancing intestinal ab-
sorption of poorly water soluble and permeable drugs.
The distinct advantage of this PLHNs have been dem-
onstrated to include the unique advantages of both lipo-
somes and polymeric nanoparticles while excluding some
of their intrinsic limitations, thereby holding great prom-
ise as a delivery vehicle for various drugs [15]. In the
present study emulsification solvent evaporation method
was used to prepare PLHN and effect of different inde-




Poly (ɛ-caprolactone) (PCL) (Mw 70,000-90,000) was
supplied as a gift sample from Sigma Aldrich, USA.Itraconazole was provided as a gift sample from Intas
Biopharmaceutical Ltd, Ahmedabad, India. Soya lecithin
30%, Polyvinyl alcohol and all other Materials like Dichlo-
romethane (DCM), Tetrahydrofuran (THF) and Mannitol
(PVA) were purchased from Himedia laboratories Pvt. Ltd,
Mumbai, India. Double Distilled Water was used through-
out the experiment.
Preparation of polymer lipid hybrid nanoparticles
PLHNs were prepared by the single emulsification evap-
oration method. In this method PCL and ITZ were dis-
solved into the DCM. Soya Lecithin with lipid to polymer
ratio of 1:10 was dissolved into the aqueous phase [16]. In
order to facilitate the solubilisation of the Soya Lecithin,
water miscible organic solvent Tetrahydrofuran (4% v/v)
was added into the aqueous solution. Polyvinyl Alcohol
(PVA) was added as a stabilising agent (0.5 to 1.5% w/v)
into the aqueous phase. The resulting PCL solution was
then added into the aqueous solution drop wise with con-
tinuous stirring and kept aside for 1 to 2 hr to evaporate
the DCM [17]. Then dispersion was centrifuged at
12,000 rpm for 30 min at room temperature and the pellet
was redispersed in the double distilled water. The disper-
sion was sonicated and frozen at −90°C for 3 hr in a deep
freezer and freeze dried (Benchtop K freeze dryer, Virtis,
4KBTZL/105, USA).
Optimization of PLHNs by box-behnken design
A Box-Behnken statistical design with 3 factors, 3 levels,
and 15 runs was selected for the optimization study and
the Design Expert® 8.0.6 software was used [18]. The in-
dependent variables selected were lipid to polymer ratio
(X1), concentration of surfactant (X2) and concentration
of drug (X3) and dependent variables were particle size
(Y1) and entrapment efficiency (% EE) (Y2) (Table 1)
with high, medium and low level. A checkpoint analysis
was performed to confirm the role of the derived poly-
nomial equation and contour plots in predicting the re-
sponses [19]. Optimization was performed to find out
the level of independent variables (X1, X2, and X3) that
would yield a minimum value of the particle size (Y1)
and maximum value of EE (Y2).
Table 2 Box-behnken experimental design with measured responses
Batch No X1 X2 X3 Particle size Y1 (nm) Entrapment efficiency Y2 (%)
PLN1 −1 −1 0 251.0 ± 0.7 80.5 ± 0.3
PLN2 1 −1 0 353.0 ± 0.2 83.0 ± 0.2
PLN3 −1 1 0 214.0 ± 0.03 78.7 ± 0.07
PLN4 1 1 0 240.0 ± 1.2 83.0 ± 0.8
PLN5 −1 0 −1 244.0 ± 0.67 80.0 ± 0.64
PLN6 1 0 −1 248.0 ± 0.8 83.4 ± 0.4
PLN7 −1 0 1 234.0 ± 0.9 77.4 ± 0.0.4
PLN8 1 0 1 264.0 ± 1.31 81.2 ± 0.09
PLN9 0 −1 −1 319.0 ± 0.02 81.8 ± 0.8
PLN10 0 1 −1 223.0 ± 0.5 80.1 ± 0.32
PLN11 0 −1 1 344.0 ± 0.45 81.0 ± 0.34
PLN12 0 1 1 234.0 ± 0.51 78.0 ± 0.23
PLN13 0 0 0 245.0 ± 0.32 79.0 ± 1.02
PLN14 0 0 0 243.0 ± 0.08 79.9 ± 0.02
PLN15 0 0 0 240.0 ± 0.4 80.0 ± 0.05
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Particle size was measured by Dynamic light Scattering
using the particle size Analyzer (Malvern Zetasizer S90,
UK). All measurements were taken by scattering light at
90° and temperature of 25°C. Dispersion was centrifuged at
12,000 rpm for 30 min at room temperature. Supernant
was discarded and the resultant pellet was redispersed in
double distilled water. Dispersion was then appropriately
diluted for the particle size measurement [20].
% Entrapment efficiency (% EE) and drug loading
Dispersion was centrifuged at 12,000 rpm for 30 min at
room temperature, supernant was discarded, the ob-
tained pellet was dissolved in DCM and drug concentra-
tion was analysed by UV/Visible Spectrophotometer at
264 nm [21]. Drug loading was determined by the direct
method as described for the EE. Measured amount of
final freeze dried formulation was dissolved into the
DCM and analysed U.V.Visible Spectrophotometer at
264 nm. It was also calculated by the indirect method by
the Equation 1.
Drug Loading ¼ Amount of ITZ entrapped½ 
Amount of ITZ Added þ Amount of Excipients Added½ 
ð1ÞTable 3 Checkpoint batches with predicted and measured va
Batch code X1 X2 X3 Partic
Predic
CP1 0 −0.5 0.5 280.54
CP2 0 0.5 0.75 230.27
P-Value 1.00Fourier transmission infrared spectroscopy (FTIR)
The samples were weighed approximately, homoge-
nously dispersed in dried KBr in a mortar and pestle,
and compressed under vacuum with compression force
using round flat face punch for three minutes to produce
pellet compact. The pellet was placed in the IR light path
and the IR spectra were recorded using a FTIR spectro-
photometer (NICOLET 6700, Thermo Scientific, USA).
Spectrum was recorded in the wavelength region of 4000–
400 cm − 1 [20].
Differential scanning calorimetry (DSC)
DSC Analysis was conducted using the Differential
Scanning Calorimeter (DSC-60, Shimadzu, Japan). Sam-
ple curves were recorded at a scan rate of 10°C/min
from 50 to 300°C. Each powder sample, 5–10 mg was
analysed by same procedure. DSC of ITZ, PCL, soya
lecithin, Mannitol, PVA, physical mixture and freeze
dried final formulation was conducted to show the com-
patibility of drug with excipients and loading of the drug
in to the polymeric matrix [22].
Powder x-ray diffraction (PXRD)
PXRD of various samples was recorded at room tem-
perature with X-Ray Diffractometer (D2Phaser-brukker,lue
le size(nm) % Entrapment efficiency
ted Measure Predicted Measure
319 ± 0.4 79.77 77.79 ± 0.2
214 ± 0.8 78.48 80.57 ± 0.17
0.995
Table 4 Optimised formulation as per the design expert®
8.0.6 software
Independent variables Criteria Value Desirability
Lipid: polymer In range 0.96
0.948
Concentration of surfactant In range 0.81
Concentration of drug In range −1
Dependent variables
Particle size Minimum 228.02
% Entrapment efficiency Maximum 83.87
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(2θ) with a step size 0.02° and a step interval of 0.1
Sec [3].
Transmission electron microscopy (TEM)
TEM of PLHNs was performed following negative
staining with Phosphotungstic acid (PTA) [5]. A drop
of dispersion (1 mg/ml) was placed on copper grids
followed by the addition of a drop of PTA. At the
end of 3 min, excess liquid was removed, the grid
air-dried and imaging conducted, using a transmis-
sion electron microscope (Holland Technai 20, Phillips,
Holland) [15].
Zeta potential
The zeta potential of the dispersion was measured by
determining the electrophoretic mobility using the
Zetasizer (Malvern Zetasizer ZS90, UK). Dispersion
was centrifuged at 12,000 rpm for 30 min at roomFigure 1 Desirability plot of the optimize PLHNs formulation.temperature. Supernant was discarded and the resultant
pellet was redispersed in double distilled water using ultra-
sonic probe system for 1 min with 50 s pulse at 200 v. Dis-
persion was then appropriately diluted and zeta potential
was measured [5].
In-vitro drug release study
Drug release was performed by dialysis method. Disper-
sion was filled in dialysis tube (2.4 nm pore size, Himedia,
India). Drug release was initiated by immersing the dia-
lysis tube in 200 ml of release media on the magnetic
stirrer at 37 ± 5°C and 50 rpm [23]. Various release
media were used for the release study like pH 7.4 phos-
phate buffer, 0.1 N HCL, pH 6.8 phosphate buffer with
3% SLS. Aliquots (5 ml) were withdrawn at specified
time points and drug concentration was measured by
UV/Visible Spectrophotometer at 264 nm. The release
data was fitted with different kinetic models such as
zero order, first order, Higuchi and Korsmeyer-Peppas
model.
Ex-vivo permeation study
Male Wistar rats (250–320 gm) were sacrificed by the
humane method. Permission for study was obtained
from the institutional animal ethics committee (Protocol
No. RPCP/IAEC/2011-2012/MPH-PT-13). All the pro-
cedures were followed as per guidelines of committee
for the purpose of control and supervision of experi-
ment on animals (CPCSEA), Division of Animal Welfare,
Ministry of Forests and Environment, Government of
India. After rats were sacrificed, the small intestine
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bled (carbogen, 95:5 O2/CO2) Ringer buffer. The je-
junum, 20 cm distal from the pyloric sphincter was used.
The tissue was rinsed with ice-cold standard Ringer buf-
fer to remove luminal content and cut into segments.
The freeze dried PLHN sample was reconstituted with
one ml of phosphate buffer pH 6.8 [24]. Resultant sample
was placed in lumen of intestine tied from one side
and then tied from other side. The tissue was placed
into organ bath filled with 40 mL of phosphate-buffer
pH7.4. Continuous aeration and constant temperature
of 37 ± 0.5°C were maintained. Samples were taken
from the receptor chamber at predetermined time inter-
val and replaced with equal volume of buffer. Aliquots
were assayed for the drug content using U.V. Visible
Spectrophotometer at 264 nm [25]. It was compared with
the simple drug solution in phosphate buffer pH 6.8.Figure 2 FTIR spectra of drug, excipients and formulation.Percentage drug permeation and permeability enhance-







Where dQ/dt is the steady-state appearance rate on
the acceptor side of the tissue, A is the area of the tissue
(cm2) and Co is the initial concentration of the drug in
the donor Compartment.
Permeability Enhancement ratio
¼ Papp of the nanoparticle formulation
Papp of the drug solution
ð3Þ
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microscopy (CLSM)
For the cell uptake studies, PLHNs were labelled with
fluorescent dye, Rhodamine B and placed into the
lumen of the intestine, and kept for 1 hr into the
phosphate buffer saline then the tissue was preserved
in to the incubation media i.e. 10% formalin for the
CLSM study [27]. The block was prepared using cryo-
protectant embedding medium. The cross section of
the intestinal tissue of 5 μm thickness was taken by
cryomicrotome (CM1850, Leica) at −20°C. The section
was placed on the slides coated with poly-L-lysine.
The slides were incubated at 37°C for the 20 min for
the fixation of the section. The slides were examined
by CLSM (Zeiss LSM S10 META) through the z axis.Figure 3 DSC thermograms of drug, excipients and formulation.Optical excitation was carried out with 480 nm and
fluorescence emission was detected above 520 nm for
Rhodamine B [28].Stability study
For stability study, freeze dried ITZ-PLHNs were stored
at room temperature (~25°C), refrigerator (4° to 8°C)
and accelerated condition (Temperature: 40 ± 2°C,
Relative humidity: 75% ± 5) over a period of 45 days
in stopper glass vials. Samples were evaluated for
particle size and drug content on 15th, 30th and
45th day. Chemical stability during the storage was
checked by FTIR spectrophotometer after 45th day
of storage [20].
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Preparation of PLHN
In the method of preparation, DCM diffuses quickly
into the aqueous solution, leaving PCL to precipitate
and form nanoparticles. Soya lecithin was self-assemble
on the surface of polymer nanoparticles through hydro-
phobic interactions to reduce the system’s free energy.
The hydrophobic tail of lipids was attached to the
hydrophobic polymer core and the hydrophilic head
group of lipids extend into the external aqueous en-
vironment [17].
Optimization of polymer lipid hybrid nanoparticle by
box-behnken design
All the batches of PLHNs were evaluated for the particle
size (Y1) and entrapment efficiency (Y2) and the resultsFigure 4 Powder X-ray diffraction crystallographs of drug, excipientsare shown in the Table 2. Full model polynomial equa-
tions for the Particle size and entrapment efficiency are
as follows:
For Particle Size,
Y1 ¼ þ 242:67 þ 13:87X1 P ¼ 0:0057ð Þ
‐ 50:88X2 P ¼ 0:0001ð Þ
þ 5:25X3 P ¼ 0:1403ð Þ
‐ 6:25X1X2 P ¼ 0:2005ð Þ
þ 6:50X1X3 P ¼ 0:1858ð Þ
‐ 3:50X2X3 P ¼ 0:4466ð Þ
þ 1:04X12 P ¼ 0:8227ð Þ
þ 33:54X22 P ¼ 0:0006ð Þ
þ 3:79X32 P ¼ 0:4294ð Þ R2 ¼ 0:9869
 
ð4Þand formulation.
Figure 5 TEM image of ITZ-PLHNs.
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‐ 0:82X2 P ¼ 0:0160ð Þ
‐ 0:96X3 P ¼ 0:0085ð Þ
þ 0:46X1X2 P ¼ 0:2153ð Þ
þ 0:10X1X3 P ¼ 0:7647ð Þ
‐ 0:32X2X3 P ¼ 0:3657ð Þ
þ 0:96X12 P ¼ 0:0361ð Þ
þ 0:70X22 P ¼ 0:0928ð Þ




Two check point batches were prepared and evaluated
for the particle size and EE as shown in Table 3. T-test
was applied between actual and predicted values of
dependent parameters and P-values are reported inFigure 6 Drug release profile for ITZ-PLHNs formulation in Phosphate
buffer pH 6.8.Table 3. At 5% significance, there was no significant dif-
ference between actual and predicted value of particle
size and entrapment efficiency.
Optimization of formulation
After studying the effect of independent variables on the
responses, the levels of these variables that give the
optimum response were determined. Hence, all the vari-
ables were decided in range and the optimum formula-
tion is one that gives lower value of particle size along
with a high amount of drug entrapped. Values of the
variables for the optimised batch are given in the Table 4.
Desirability of the optimized batch was found to be
0.948 which is shown in Figure 1.
Particle size, entrapment efficiency and drug loading
Particle size was found to be in the range of 214.0 to
353.0 nm. Particle size of each batch is given in the
Table 2. Particle size of the optimized batch was
210.7 ± 1.8 nm and PDI was 0.53 ± 0.67. Entrapment effi-
ciency was found to be in the range of 77.4 to 83.4%. EE
of each batch is given in the Table 2. Drug loading of the
optimized batch determined by both direct and indirect
method were 1.67% and 1.72%, respectively.
Freeze drying
The freeze dried formulation was found to be soft, white,
and amorphous in nature. There was no significant increase
in particle size observed (at 5% significant level) after freeze
drying as compared to freshly prepared formulation.
FTIR spectroscopy
FTIR spectra of the drug, polymer, lipid, Mannitol, phys-
ical mixture and freeze dried formulation are shown in
Figure 2. FTIR spectra of freeze dried formulation shows
all the characteristic peak of the all components and not
shown any additional new peak. The spectra of PLHNbuffer pH 7.4, 0.1 N Hydrochloric acid and Phosphate
Table 6 Papp and permeability enhancement ratio of the
ITZ solution and formulation
Type of formula Papp(cm/sec) Permeability enhancement ratio
PLHNs Formulation 2.39 × 10−3 1.476
ITZ Solution 1.61 × 10−3 1
Table 5 Kinetic release parameter of ITZ-PLHNs
Release media Zero order First order Higuchi Koresmayer-Pepas
R2 k0 (h
−1) R2 k1(h
−1) R2 kH (h
-1/2) R2 n value
P.B pH 7.4 0.786 1.77 0.966 −0.01 0.975 15.16 0.9732 0.79
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1052.01, 1378.15 cm−1 [29], PCL at 2925.28 cm−1 and
peak of the Soya lecithin at 2925.28, 1437.68 cm−1, PVA
at 1735.73, 1652.65 cm−1 Mannitol at 1247.40 cm−1.
Thus this result indicates that there was no formation of
the new peak, so drug and excipients are compatible
with each other and also revealed that ITZ was success-
fully incorporated into the PLHNs.
Differential scanning calorimetry (DSC)
DSC thermograms of the Formulation, Physical mixture,
ITZ, PCL, Soya lecithin, PVA and Mannitol are shown
in Figure 3. DSC spectra of formulation and physical
mixture gives the sharp peak at 161.0°C and 167.0°C, re-
spectively which is the peak of mannitol and it does not
show any new peak or additional peak. So, it is revealed
that the excipients are compatible with the drug and
there is no any reaction between the drug and excipients
[3]. The melting endothermic peak of ITZ was observed
at 168.04°C while the thermogram of the lyophilized ITZ
incorporated PLHNs does not show the endothermic
peak for ITZ [20].
Powder x-ray diffraction (PXRD)
The diffractograms shown in Figure 4 further confirmed
the results of DSC thermal analysis. ITZ powder showed
strong typical peaks of crystalline ITZ at 2θ scattered an-
gles 14.49°, 17.53°, 20.38°, 23.5° and 25.29°. The presence of
sharp peaks indicates crystalline nature of ITZ. The charac-
teristic peak of ITZ was not observed in PLHNs at corre-
sponding 2θ scattered angles indicating that the drug was
encapsulated in the polymer and lipid carrier and also con-
firms that amorphous form of the formulation [3,20].
Transmission electron microscopy (TEM) morphology and
zeta potential
The TEM image of ITZ-PLHNs is shown in Figure 5.
The particles were spherical in shape and show the dim
ring of lipid coat surrounding the polymeric core. The
particle size was observed between 160–200 nm and is
comparable to the results of particle size by particle size
analyzer [15]. Zeta potential of the optimized ITZ-
PLHNs was found to be −11.7 mV which is attributed to
the non-ionic nature of the surfactant PVA as opposed
to the anionic nature of the soya lecithin. Because of the
negative zeta potential, it produces repulsion betweenthe nanoparticles and prevents the aggregation which
gives the long-time stability [5,16].
In-vitro drug release
With the selection of lipid and polymer ratio, the release
kinetics of PLHNs showed some unique features. There
was absence of initial burst release observed, may be due
to the uniform distribution of ITZ in the PLHNs matrix
rather than just on the PLHNs surface. Drug released
from the PLHN generally occurs through the drug diffu-
sion and the polymer erosion mechanism. Sustained ITZ
release from the PLHNs is attributed to the lipid matrix
imparting a barrier to drug release [17].
Drug release profile of the ITZ-PLHNs in phosphate
buffer pH 7.4, 0.1 N HCl and phosphate buffer pH 6.8 is
shown in the Figure 6. The release profiles were fitted to
various kinetic models such as zero-order, first-order,
Higuchi equation and Korsmeyer–Peppas equation. ITZ
release profile followed Higuchi model in the release
media phosphate buffer pH 7.4 ( R2 = 0.98) as shown in
Table 5 [30,31]. All the kinetic data were fitted to the
Korsmeyer-Peppas Equation. Here n > 0.79, the drug is
released from polymeric matrix system followed anomal-
ous diffusion mechanism.
Ex-vivo permeability
Ex-vivo permeability studies are relevant approaches to
evaluate the absorption enhancing effect of a colloidal
drug carrier system on the intestinal tissue. Table 6
shows the comparison of the ex-vivo permeability of ITZ
solution and ITZ-PLHN formulation. Figure 7 shows the
% permeability of ITZ formulation after 240 min is 30%.
Measurement of the apparent permeability coefficient
(Papp) and the absorption enhancement ratio of PLHNs
indicated that there is an increase in the permeability of
ITZ from the ITZ-PLHN formulation [25,32].
In-vitro cellular uptake study with CLSM
The cellular uptake of the PLHNs was examined to
demonstrate the penetration of the nanoparticles across
Figure 8 CLSM images of Rhodamine B labelled ITZ PLHNs A. combined three dimensional images, B. images of intestinal villi optically
sectioned in the x-y plane at regularly spaced distances along the z-axis.
Figure 7 % cumulative ITZ Permeability of the ITZ solution and formulation.
Gajra et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:3 Page 10 of 15
Figure 9 FTIR spectra of formulation after 45 days for Room
temperature, refrigerated condition and accelerated condition.
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increase in the intestinal permeability of ITZ. The in-
ternalization of Rhodamine B loaded NPs incubated for
1 hr was visualized by CLSM. Figure 8(B) shows CLSM
images of Rhodamine B labelled PLHNs treated intes-
tinal villi optically sectioned in the x-y plane at regularly
spaced distances along the z-axis whereas Figure 8(A)
shows combined image containing Rhodamine labelled
PLHNs internalized and distributed in the small intestinal
mucosal cross-sections. The CLSM images show strong
red fluorescent spherical particles in the intestinal villi of
rat both on the surface of the intestinal enterocyte and on
the M- cells [22]. Villi and microvillus of the intestinal tis-
sue was stained red with the dye and Rhodamine B labelled
nanoparticles are highlighted with red fluorescence [28].
Stability study
Stability study was carried out to know the chemical
changes that may occur in the formulations. Table 7 shows
the stability study data of particle size and drug content of
ITZ-PLHNs formulation. Particle size of the formulation
was increased slightly in accelerated, room temperature
and refrigeration condition and drug content was de-
creased slightly from 96% to 95% for all the condition. No
significant change in the particle size and drug content was
revealed. FTIR spectra of the formulation after 45 days at
room temperature, accelerated condition and refrigerated
condition are shown in the Figure 9. It was revealed that
there is no change as it shows the main peak of the drug
intact at 2934.76, 1459.52, 1376.81, 1193.64 cm−1.
Discussion
Effects of independent variables on particle size
For the particle size value of the correlation coefficient
(R2) of the polynomial equation (Equation 4) was foundTable 7 Stability study data for ITZ-PLHNs formulation
Day Particle size (nm) Assay (%)
First 232.8 ± 0.21 96.38 ± 0.02
Accelerated condition
15 245.3 ± 0.35 96.29 ± 0.04
30 249.5 ± 0.61 95.50 ± 0.03
45 249.9 ± 0.32 95.39 ± 0.02
Room condition
15 230.3 ± 0.31 96.30 ± 0.04
30 230.8 ± 0.34 96.28 ± 0.05
45 231.4 ± 0.41 96.25 ± 0.021
Refrigerator condition
15 248.6 ± 0.32 96.12 ± 0.023
30 250.3 ± 0.23 95.43 ± 0.034
45 256.7 ± 0.36 95.28 ± 0.04to be 0.9869, indicating good fit of the model. Among
the independent variable selected, X1, X2, X2
2; lipid to
polymer ratio, concentration of surfactant and square of
the concentration of surfactant, respectively, are signifi-
cant model terms (P < 0.05).
Here, variable X1 and X2
2 have positive effect on par-
ticle size as revealed by positive value of coefficient in
the equation, it means that as lipid to polymer ratio (X1)
increases, particle size increases and X2 has negative
effect on particle size as revealed by negative value
of coefficient in the Equation 4 it means that as the
concentration of surfactant (X2) increases particle size
decreases.
From the response surface 3D plot for the particle size
(Figure 10A), it was observed that as the concentration
of surfactant increases, particle size decreases. This may
be due to the reason that at lower concentration of PVA,
it exists as a single molecule layer at surface of particle
and at higher concentration it exists as an aggregated
form and has an enhanced surfactant activity. It may
also be due to effective reduction in the interfacial ten-
sion between aqueous and organic phase [33]. As the
lipid to polymer ratio increases, particle size increases.
This increase in the particle size may be because of in-
crease in the viscosity of the inner polymeric phase
that affects the shearing capacity of the mechanical
stirrer [15,34].
Thus, the effect of the lipid to polymer ratio and the
concentration of surfactant were significant, as it is evi-
dent from their high coefficients and the fact that the
bars corresponding to variables X1, X2 and X2
2 extend
beyond the reference line in Pareto chart (Figure 10B).
Figure 10 Response surface 3D plot (A) showing the effect of different variables on particle size and Pareto chart (B) showing the
variables having P value greater than 0.05.
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not significant so they were removed from the equation to
generate the reduced model Equation 6 [19].
Reduced model equation for particle size Y1ð Þ ¼
þ 242:67 þ 13:87X1‐ 50:88X2 þ 33:54X22
ð6Þ
Effects of independent variables on entrapment
efficiency (EE)
For Entrapment efficiency, the value of the correlation
coefficient (R2) of the Equation 5 was found to be
0.9540, indicating good fit of the model. Among all the
independent variables X1, X2, X3, X1
2; lipid to polymer
ratio, concentration of surfactant, concentration of thedrug and square of the concentration of drug, respect-
ively, are significant model terms (P < 0.05).
Here, variables X1 has positive effect on EE as revealed
by the positive value of coefficient in the Equation 5,
means as lipid to polymer ratio increases, EE increases
and X2 and X3 has negative effect on EE as revealed by
the negative value of coefficient in the Equation 5, it
means that as concentration of surfactant and concen-
tration of the drug increases, EE decreases.
From the response surface 3D plot for the EE
(Figure 11A), it shows that as the concentration of sur-
factant increases, EE decreases. This may be due to de-
crease in the particle size. It may also be due to increases
the partition of the drug from internal to external phase
of the medium at the high concentration of surfactant
[34]. Figure 11B shows that as the lipid-polymer ratio in-
creases, EE increases. This may be due to increase in the
Figure 11 Response surface graphs (A,B,C) showing effect of different variables on % entrapment efficiency and Pareto chart (D)
showing variables having P value greater than 0.05.
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the drug and lipid layer at the surface of the polymer
matrix and also reduces the escaping of the drug into ex-
ternal phase. Figure 11C shows that as the concentration
of the drug increases, EE decreases. It may be due to rea-
son that because ITZ is insoluble in water so at high con-
centration some amount of the drug may precipitate out.
Thus, the effect of the lipid to polymer ratio, the con-
centration of surfactant and concentration of drug were
significant, as it is evident from their high coefficients
and the fact that the bars corresponding to variables X1,
X2, X3 and X1
2 extend beyond the reference line in Pareto
chart (Figure 11D) for the EE. P value greater than 0.05 in-
dicates that the model terms were not significant so they
were removed from the equation to generate the reduced
model Equation as:
Entrapment efficiency Y2ð Þ ¼
þ 79:63 þ 1:75X1‐ 0:82X2‐ 0:96X3 þ 0:96X12
ð7Þ
In this study, the model was checked for lack of fit for
both the responses; Particle size and EE. For lack of fit
P values obtained for particle size and EE were 0.0524
and 0.3965, respectively and hence the current model
provided a satisfactory fit to the data (P > 0.05) and has
no lack of fit [19].
The derived polynomial equations and contour plots
from the Box Behnken experimental design aid in pre-
dicting the values of selected independent variables for
preparation of optimized PLHN formulations with de-
sired properties. Factorial design was validated by check
point analysis. From the result of the check point ana-
lysis P value calculated was greater than 0.05 so the
model was validated. Optimized batch was selected based
on overall desirability factor and having less particle size
and high entrapment efficiency.
Optimized formulation was freeze dried to white,
amorphous powder which was readily redispersed in to
the water. FTIR and DSC of the freeze dried formulation
indicate that the drug was satisfactorily incorporated in to
the nanoparticles. XRD study revealed that ITZ loaded
PLHNs were amorphous in nature. Morphology of PLHNs
indicates that it has lipid surrounding the polymeric core
and particles were spherical in shape. Optimized formula-
tion was followed the Higuchi model for the drug release
which indicates diffusion type of drug release from the
matrix. Ex vivo permeability study indicates higher appar-
ent permeability coefficient (Papp) for the ITZ-PLHNs for-
mulation in comparison to the drug solution which
confirms increase in drug permeability. This is also indi-
cated by high permeability enhancement ratio.
The NPs absorption occurs in rat follicular mucosa
(Peyer’s patches) as well as non-follicular mucosa (normalenterocyte) as visualized in CLSM images. Interaction of
NPs with M-cells of the Peyer’s patches would suggest that
NPs were concentrated on the follicle associated epithe-
lium promoting the absorption through M cells. The red
coloured particles clearly show internalization of the ITZ
loaded PLHNs in the intestinal villi. From the results it
could be concluded that no single mechanism appears
dominant in ITZ loaded PLHNs uptake. Transcellular,
Paracellular transport and endocytosis through M-cells of
Peyer’s patches may be the mechanisms by which the
PLHNs facilitate ITZ absorption.
Stability study of the final optimized formulation re-
vealed that there is no any major change in the particle
size and drug content during the time period of 45 days.
FTIR spectra of the formulation after 45 days revealed
that the drug was in the stable form as the main peak of
the drug was present unchanged into the spectra. Thus,
Formulation does not give any physical and chemical
changes at various environmental conditions for the period
of 45 days.
Conclusion
In the present work, ITZ-PLHNs consisting of the poly-
meric core and lipid layer at the interface of the core
were easily prepared by single emulsification evaporation
method with tunable particle size and high entrapment
efficiency. Box Behnken design was successfully applied
to optimize the effect of lipid to polymer ratio, concen-
tration of surfactant and concentration of drug on par-
ticle size and EE. The derived polynomial equations and
contour plots aid in predicting the values of selected in-
dependent variables for preparation of optimum ITZ
formulations with desired properties. Thus, PLHNs may
help to improve the oral bioavailability as they directly
penetrate in to the systemic circulation by lymphatic
uptake, M cells of payer’s patch and paracellular path-
way that may reduce the effect of food and hepatic first
pass metabolism in comparison with the conventional
system.
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